Evidence map›Paper›PMID 41840224›Full record

ReviewOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2026

Research progress of drug-induced osteoporosis.

Wenbin Tan, Ting He, Jia Li

Abstract readReview
PubMed Publisher
In one paragraph

Review in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Wenbin TanThe First School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, China.
Ting HeThe First School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, China.
Jia LiThe First School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, China. gdnflj@smu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug-induced osteoporosis (DIO) is an important part of secondary osteoporosis. This article discusses the effects of common drugs on bone metabolism and the possible mechanisms leading to osteoporosis and discusses the possible treatment strategies. Although anti-osteoporosis drugs can effectively improve bone mineral density and reduce the risk of fracture and prevent the occurrence of DIO, long-term use of anti-osteoporosis drugs may lead to skeletal adverse events such as atypical femur fracture. Therefore, for the prevention and treatment of DIO, the benefits and adverse reactions of drugs should be comprehensively considered to develop an individualized treatment plan for patients.

Indexed as

5-α reductase inhibitorAntidepressant drugsAntineoplastic drugsGlucocorticoidsLevothyroxineOpioidsProton pump inhibitorsSecondary osteoporosis

Identifiers

PMID41840224

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.